Selenium supplementation in HIV-infected individuals: A systematic review of randomized controlled trials
Selenium supplementation in HIV-infected individuals: A systematic review of randomized controlled trials
Muzembo et al., 2019 | Clin Nutr ESPEN | Systematic Review
Citation
Muzembo Basilua Andre, Ngatu Nlandu Roger, ... Ikeda Shunya. Selenium supplementation in HIV-infected individuals: A systematic review of randomized controlled trials. Clin Nutr ESPEN. 2019-Dec;34:1-7. doi:10.1016/j.clnesp.2019.09.005
Abstract
BACKGROUND & AIM: HIV infection has been linked to selenium deficiency which, in turn, is thought to be associated with a high risk of tuberculosis and mortality in HIV-infected patients. Furthermore, several trials have reported the beneficial effects of selenium supplementation in patients with HIV. However, the evidence remains inconclusive. Our study aimed to investigate whether daily selenium supplementation in patients infected with HIV delays the progression of HIV infection. METHODS: A systematic review was performed using EMBASE and Medline databases from January 2000 to June 2018. We included randomized clinical trials in adults comparing selenium with placebo and reporting outcomes including its effect on HIV viral load and cluster of differentiation 4 cell count (CD4). RESULTS: Six out of the 507 retrieved articles that met the inclusion criteria were used in this review. Reviewed studies show that daily supplementation with 200 μg selenium may improve the rate of cluster of differentiation 4 (CD4) count. The length of selenium supplementation and follow-up varied from 9 to 24 months. Supplements were well tolerated in all reviewed studies. Whether daily selenium supplementation in HIV-infected persons suppresses HIV-infection requires further investigation as existing data are heterogeneous. CONCLUSIONS: We found some clinical evidence that selenium supplementation can delay CD4 decline in HIV-infected patients, thus prolonging the onset of AIDS. However, we did not find quantifiable evidence that selenium supplementation suppresses or reduces HIV viral load.
Key Findings
Six out of the 507 retrieved articles that met the inclusion criteria were used in this review. Reviewed studies show that daily supplementation with 200 μg selenium may improve the rate of cluster of differentiation 4 (CD4) count. The length of selenium supplementation and follow-up varied from 9 to 24 months. Supplements were well tolerated in all reviewed studies. Whether daily selenium supplementation in HIV-infected persons suppresses HIV-infection requires further investigation as existing
Outcomes Measured
- Requires manual extraction
Population
| Field | Value |
|---|---|
| Population | hiv |
| Sample Size | See abstract |
| Age Range | See abstract |
| Condition | deficiency |
MeSH Terms
- Adult
- CD4 Lymphocyte Count
- Databases, Factual
- Dietary Supplements
- Disease Progression
- HIV Infections
- Humans
- Randomized Controlled Trials as Topic
- Selenium
- Selenomethionine
Evidence Classification
- Level: Systematic Review
- Publication Types: Journal Article, Systematic Review
- Vertical: selenium
Provenance
- PMID: 31677697
- DOI: 10.1016/j.clnesp.2019.09.005
- PMCID: Not in PMC
- Verified: 2026-04-09 via PubMed E-utilities API
Source extracted via PubMed E-utilities API on 2026-04-09